A new national study led by researchers at the University of Delaware and George Mason University highlights significant ...

Merck's Winrevair gains FDA priority review for PAH label update after ZENITH trial shows major reduction in serious events and strong clinical impact.

PAH patients with cardiovascular disease risk had similar hospitalization and mortality rates as those without after a ...

Panelists discuss recent trial data demonstrating that a novel agent not only slows lung function decline but also delays ...

Merck (MRK) stock in focus as its lung disease drug Winrevair gains FDA priority review for a label update based on Phase 3 ...